| ELI Lilly & Coannounced 30 Oct 2025 |
Submit orforglipron for obesity to global regulatory authorities |
Met31 Dec 2025 |
| ELI Lilly & Coannounced 13 Dec 2022 |
Report Phase 3 clinical trial data for donanemab |
Met31 Dec 2023 |
| ELI Lilly & Coannounced 13 Dec 2022 |
Initiate Phase 3 clinical trials for retatrutide in obesity |
No record found31 Dec 2023 |
| ELI Lilly & Coannounced 1 Nov 2022 |
Initiate a rolling submission for tirzepatide in obesity |
Met31 Dec 2022 |
| ELI Lilly & Coannounced 1 Nov 2022 |
Complete the submission for tirzepatide in obesity |
Met30 Apr 2023 |
| ELI Lilly & Coannounced 4 Aug 2022 |
Make bebtelovimab commercially available for purchase |
Met21 Aug 2022 |
| ELI Lilly & Coannounced 3 Feb 2022 |
Submit regulatory applications for lebrikizumab and mirikizumab |
Met31 Dec 2022 |
| ELI Lilly & Coannounced 15 Dec 2021 |
Complete the rolling submission for donanemab |
Late31 Mar 2022 |
| ELI Lilly & Coannounced 15 Dec 2021 |
Initiate a phase 3 study for prostate cancer treatment |
No record found30 Jun 2022 |
| ELI Lilly & Coannounced 15 Dec 2021 |
Complete the rolling submission for pirtobrutinib |
Met31 Dec 2022 |
| ELI Lilly & Coannounced 15 Dec 2021 |
Progress weekly insulin to phase 3 studies |
No record found31 Dec 2022 |
| ELI Lilly & Coannounced 15 Dec 2021 |
Move N3PG-IV antibody into pivotal trials |
No record found31 Dec 2022 |
| ELI Lilly & Coannounced 26 Oct 2021 |
Submit tirzepatide for regulatory approval in additional markets |
Met31 Dec 2021 |
| ELI Lilly & Coannounced 3 Aug 2021 |
Submit donanemab for Alzheimer’s disease to regulatory authorities |
Met31 Dec 2021 |
| ELI Lilly & Coannounced 3 Aug 2021 |
Submit tirzepatide for type 2 diabetes to regulatory authorities |
Met31 Dec 2021 |
| ELI Lilly & Coannounced 3 Aug 2021 |
Submit a biologics license application for donanemab |
Met31 Dec 2021 |
| ELI Lilly & Coannounced 3 Aug 2021 |
Submit the registration package for tirzepatide to regulatory authorities |
No record found31 Dec 2021 |
| ELI Lilly & Coannounced 29 Jan 2021 |
Deliver 500,000 additional doses of bamlanivimab to the U.S. government |
Withdrawn31 Mar 2021 |
| ELI Lilly & Coannounced 23 Apr 2020 |
Complete the second Phase 3 study of mirikizumab |
No record found31 Dec 2020 |
| ELI Lilly & Coannounced 30 Jan 2020 |
Make lower-priced versions of Humalog Mix75/25 KwikPen and Humalog Junior KwikPen available |
No record found15 Apr 2020 |
| ELI Lilly & Coannounced 17 Dec 2019 |
Launch up to three new medicines |
No record found31 Dec 2020 |
| ELI Lilly & Coannounced 17 Dec 2019 |
Report data readouts for several investigational medicines |
Met31 Dec 2020 |
| Lilly ELI & Co.announced 30 Jul 2019 |
Complete the Trulicity clinical trial |
No record found31 Dec 2019 |
| Lilly ELI & Co.announced 6 Feb 2019 |
Launch an exchange offer to divest remaining ownership interest in Elanco Animal Health |
Met30 Jun 2019 |
| Lilly ELI & Co.announced 7 Jan 2019 |
Close the acquisition of Loxo Oncology |
Met31 Mar 2019 |
| Lilly ELI & Co.announced 6 Nov 2018 |
Begin Phase 3 studies for type 2 diabetes |
Met31 Mar 2019 |
| Lilly ELI & Co.announced 6 Nov 2018 |
Submit URLi to regulatory authorities |
No record found31 Dec 2019 |
| Lilly ELI & Co.announced 24 Jul 2018 |
Submit Taltz for U.S. regulatory approval in Ankylosing Spondylitis |
No record found31 Dec 2018 |
| Lilly ELI & Co.announced 24 Apr 2018 |
Initiate regulatory submissions for Cyramza |
No record found30 Jun 2018 |
| Lilly ELI & Co.announced 13 Dec 2017 |
Launch a new indication for Taltz in psoriatic arthritis |
Met31 Dec 2018 |
| Lilly ELI & Co.announced 24 Oct 2017 |
Resubmit the New Drug Application for baricitinib |
Met31 Jan 2018 |
| Lilly ELI & Co.announced 24 Oct 2017 |
Submit a New Drug Application for lasmiditan |
Met31 Dec 2018 |
| Lilly ELI & Co.announced 25 Apr 2017 |
Initiate global submissions for abemaciclib results |
No record found30 Jun 2017 |
| Lilly ELI & Co.announced 25 Apr 2017 |
Begin global submissions for abemaciclib results |
No record found30 Sep 2017 |